Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000392001 | SCV000330719 | pathogenic | not provided | 2016-08-12 | criteria provided, single submitter | clinical testing | The R344X variant in the SMCHD1 gene has been reported previously as a de novo pathogenic variant in an individual with FSHD2 (Lemmers et al., 2015). This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The R344X variant was not observed in approximately 6,000 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. We interpret R344X as a pathogenic variant |
Labcorp Genetics |
RCV000791844 | SCV000931109 | pathogenic | Facioscapulohumeral muscular dystrophy 2 | 2019-01-29 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg344*) in the SMCHD1 gene. It is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with SMCHD1-related disease. ClinVar contains an entry for this variant (Variation ID: 280772). Loss-of-function variants in SMCHD1 are known to be pathogenic (PMID: 23143600). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000791844 | SCV004041348 | pathogenic | Facioscapulohumeral muscular dystrophy 2 | 2023-08-04 | criteria provided, single submitter | clinical testing |